Search

Your search keyword '"ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology."' showing total 12 results

Search Constraints

Start Over You searched for: Descriptor "ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology." Remove constraint Descriptor: "ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology." Topic oncol 3: translational research ncmls 2: immune regulation. Remove constraint Topic: oncol 3: translational research ncmls 2: immune regulation.
12 results on '"ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology."'

Search Results

1. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.

5. Phase 1 Radioimmunotherapy Study with Lutetium 177-labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.

6. Dual contrast agent for computed tomography and magnetic resonance hard tissue imaging.

7. Reply to John Samuel Banerji's Letter to the Editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-Labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma. Eur Urol 2013;63:1101-6.

9. Expression and clinical relevance of MET and ALK in Ewing sarcomas.

11. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.

Catalog

Books, media, physical & digital resources